Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction, Goodwin Procter is representing Graphite Bio and Latham & Watkins is representing the placements...
LENZ Therapeutics’ Merger with Graphite Bio
JURA Bio’s $16.1 Million Financing and Replay Collaboration
Wilson Sonsini Goodrich & Rosati advised JURA Bio on both the financing transaction and the collaboration agreement. JURA Bio announced a research collaboration with Syena, a cell...
Oricell Therapeutics’ $45 Million Series B1 Financing
Wilson Sonsini Goodrich & Rosati advised RTW Investments on the deal. Oricell Therapeutics Co., Ltd, a China-based innovative pharmaceutical company committed to the development of tumor...
Pearl Health’s $75 Million Series B
Wilson Sonsini advised a16z on the deal. Pearl Health, a leading technology company focused on physician enablement and risk bearing in value-based care, announced it has...
Arcellx’s $4 Billion Collaboration with Kite
Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction. Clinical-stage biotechnology company Arcellx and Gilead-owned biopharmaceutical company Kite announced a global strategic collaboration to develop...
ATP’s Launch of Ascidian Therapeutics
Wilson Sonsini Goodrich & Rosati advised Ascidian Therapeutics on the deal. Life sciences venture capital firm ATP announced the launch of new biotechnology company Ascidian Therapeutics....
Rivus Pharmaceuticals’ $132 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised RA Capital Management on the deal. Rivus Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to improving cardio-metabolic health, announced the completion...
Faeth Therapeutics’ $47 Million Series A Financing
Wilson Sonsini advised Faeth Therapeutics on the deal. Faeth Therapeutics, a cancer metabolism company, announced the completion of a Series A financing of $47 million led...
Arcellx’s $112 Million Public Offering
Wilson Sonsini advised Arcellx on the deal. Arcellx, a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other...
Cellino’s $80 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Cellino on the deal. Cellino Biotech, an autonomous cell therapy manufacturing company, announced the completion of a Series A financing...
Lycia Therapeutics’ $70 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised RTW Investments on the deal while Fenwick & West represented Lycia Therapeutics. Lycia Therapeutics, Inc., a leader in extracellular protein...
Vigil Neuroscience’s $90 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised Vida Ventures on the deal while Goodwin Procter represented Vigil Neuroscience. Vigil Neuroscience, a biotechnology company harnessing the power of...